They thus concluded that melatonin exerts anti-metastatic effects on prostate cancer via MT1 mediated inhibition of the PLC and p38 pathways, resulting in the inactivation of c-Jun with ultimate suppression of MMP-13. The gene discussed is MMP13; the disease is prostate carcinoma.